Department of Acupuncture & Moxibustion Medicine, Graduate School, Kyung Hee University, Seoul, South Korea.
Department of Acupuncture & Moxibustion Medicine, Kyung Hee University, Seoul, South Korea.
Complement Ther Med. 2018 Dec;41:23-28. doi: 10.1016/j.ctim.2018.08.006. Epub 2018 Aug 24.
To evaluate the risk of bleeding-related adverse events after acupuncture treatment in patients receiving anticoagulant or antiplatelet drugs.
A total of 428 inpatients who received acupuncture treatment underwent two assessments for bleeding-related adverse events, such as micro-bleeding, hematoma, and ecchymosis: 1) immediately after acupuncture treatment on the first day and 2) before acupuncture treatment on the following day. Additional analyses were performed using the number of acupuncture needles as independent variables. Multivariable analysis using factors likely related to bleeding and subgroup analysis according to regions of needle insertion were also performed.
A total of 169 patients receiving anticoagulant or antiplatelet drugs (exposure group) and 259 patients not receiving either drug (non-exposure group) were studied. Sixty-five (38.5%) patients in the exposure group and 115 (44.4%) patients in the non-exposure group had bleeding-related mild adverse events. There was no difference in the risk of bleeding-related adverse events between the two groups per sessions (relative risk (RR) 0.87, 95% confidence interval (CI), 0.69-1.10) and per needles (RR 0.89, 95% CI 0.70-1.13). In multivariable analysis, thickness of needle only increased risk of bleeding. Subgroup analysis showed that taking these drugs did not increase the risk of bleeding in any of the regions.
Our findings suggest that anticoagulant and antiplatelet drugs do not increase the incidence of bleeding-related adverse events after acupuncture treatment.
评估接受抗凝或抗血小板药物治疗的患者接受针刺治疗后与出血相关的不良事件的风险。
共有 428 名接受针刺治疗的住院患者接受了两次与出血相关的不良事件（如微出血、血肿和瘀斑）评估：1）针刺治疗后的第一天立即进行；2）第二天针刺治疗前进行。使用针刺针数量作为自变量进行了额外分析。还进行了多变量分析，使用可能与出血相关的因素和根据针刺部位的亚组分析。
共研究了 169 名接受抗凝或抗血小板药物（暴露组）和 259 名未接受任何药物（非暴露组）的患者。暴露组中有 65 名（38.5%）患者和非暴露组中有 115 名（44.4%）患者出现与出血相关的轻度不良事件。两组间每次治疗（相对风险（RR）0.87，95%置信区间（CI）0.69-1.10）和每针（RR 0.89，95%CI 0.70-1.13）的出血相关不良事件风险无差异。多变量分析显示，针刺深度仅增加出血风险。亚组分析显示，在任何部位使用这些药物均不会增加出血风险。
我们的研究结果表明，抗凝和抗血小板药物不会增加针刺治疗后与出血相关的不良事件的发生率。
